Tarsus Pharmaceuticals, Inc. (TARS): Net Income
-$66.42M
Year ended 2025-12-31
-$46.48M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$66.42M | n/m | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | -$115.55M | n/m | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | -$135.89M | n/m | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | -$62.09M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | -$13.83M | n/m | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | -$26.81M | n/m | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | -$4.67M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$1.32M | n/a | 2021-03-31, From 2018-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$66.42M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$35.51M | n/m |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.93M | -25.7% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $204.83M | +129.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$77.67M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$59.50M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $16.52M | +59.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $48.89M | n/m |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$390.98M | n/m |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗